LeMaitre Vascular (NASDAQ:LMAT) Price Target Raised to $118.00

LeMaitre Vascular (NASDAQ:LMAT) had its target price raised by Citizens Jmp from $113.00 to $118.00 in a report released on Thursday,Benzinga reports. They currently have a market outperform rating on the medical instruments supplier’s stock.

A number of other brokerages have also recently weighed in on LMAT. Wall Street Zen raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Weiss Ratings downgraded shares of LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday. Zacks Research lowered shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Roth Mkm reissued a “buy” rating and issued a $108.00 target price on shares of LeMaitre Vascular in a report on Wednesday, November 5th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $95.00 target price on shares of LeMaitre Vascular in a research note on Monday, November 10th. Three equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, LeMaitre Vascular has a consensus rating of “Hold” and an average price target of $105.80.

LeMaitre Vascular Trading Down 4.8%

NASDAQ:LMAT opened at $108.18 on Thursday. The company has a quick ratio of 11.45, a current ratio of 13.58 and a debt-to-equity ratio of 0.44. The business’s 50 day moving average is $87.02 and its two-hundred day moving average is $88.36. LeMaitre Vascular has a 52 week low of $71.42 and a 52 week high of $115.33. The company has a market cap of $2.45 billion, a PE ratio of 43.10, a P/E/G ratio of 2.19 and a beta of 0.72.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.01. The business had revenue of $64.45 million during the quarter, compared to the consensus estimate of $62.98 million. LeMaitre Vascular had a return on equity of 15.02% and a net margin of 23.13%.The business’s quarterly revenue was up 15.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.49 EPS. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. On average, analysts predict that LeMaitre Vascular will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 26th. Shareholders of record on Thursday, March 12th will be paid a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Thursday, March 12th. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.20. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 31.87%.

Institutional Investors Weigh In On LeMaitre Vascular

Large investors have recently made changes to their positions in the company. Mercer Global Advisors Inc. ADV boosted its position in shares of LeMaitre Vascular by 11.5% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 3,606 shares of the medical instruments supplier’s stock worth $292,000 after buying an additional 371 shares during the period. NewEdge Advisors LLC increased its position in LeMaitre Vascular by 4.6% in the 4th quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock valued at $256,000 after acquiring an additional 139 shares during the period. Empowered Funds LLC bought a new stake in LeMaitre Vascular during the 4th quarter valued at $289,000. nVerses Capital LLC bought a new stake in LeMaitre Vascular during the 4th quarter valued at $234,000. Finally, Voloridge Investment Management LLC boosted its position in LeMaitre Vascular by 70.0% during the 4th quarter. Voloridge Investment Management LLC now owns 62,909 shares of the medical instruments supplier’s stock worth $5,102,000 after acquiring an additional 25,901 shares during the period. Institutional investors and hedge funds own 84.64% of the company’s stock.

Key Stories Impacting LeMaitre Vascular

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Q4 results beat and above‑consensus guidance: LeMaitre reported $0.68 EPS vs. $0.67 consensus and revenue of $64.45M (vs. $62.98M est.); management raised Q1 and FY2026 EPS and revenue guidance, signaling continued top‑line momentum. Press Release
• Positive Sentiment: Dividend increase: Company raised the quarterly dividend 25% to $0.25/share (ex‑dividend March 12), returning cash to shareholders and supporting income‑oriented demand.
• Positive Sentiment: Analyst bullishness: Multiple firms raised ratings/targets — Citizens JMP to $118 (market outperform) and Roth MKM reaffirmed Buy and raised target to $117 — these are constructive for sentiment. Analyst Note
• Neutral Sentiment: Investor outreach: Management will participate in five investor conferences in March, increasing visibility and allowing direct Q&A with investors. Conference Notice
• Neutral Sentiment: Earnings call coverage and transcripts are available for deeper color on drivers (procedure volumes, product mix, backlog) for investors doing fundamental diligence. Earnings Transcript
• Negative Sentiment: Mixed analyst targets; some firms still imply downside: Wells Fargo raised its target but keeps an “equal weight” rating with a $94 target (below current price), and a few targets remain lower than the stock’s recent level — this can trigger profit‑taking or short‑term selling. Analyst Notes

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.